[Current status of treatment of refractory ascites in patients with liver cirrhosis].
Zhonghua Gan Zang Bing Za Zhi
; 24(10): 721-723, 2016 Oct 20.
Article
em Zh
| MEDLINE
| ID: mdl-27938554
Ascites is a common clinical manifestation of cirrhotic portal hypertension, and about 60%-80% of cirrhotic patients develop the symptom of ascites within 10 years. Once ascites occurs, the 5-year survival rate is reduced from 80% to 50%. With the progression of liver diseases, approximately 5%-10% of patients with ascites develop refractory ascites, and the median survival time is only 6-12 months. This article reviews the definition and diagnosis of refractory ascites, evaluation of prognostic factors, and treatment regimens, including large-volume paracentesis combined with protein supplementation, transjugular intrahepatic portosystemic shunt, and liver transplantation.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ascite
/
Paracentese
/
Derivação Portossistêmica Transjugular Intra-Hepática
/
Cirrose Hepática
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2016
Tipo de documento:
Article